News

GLONGHUI April 13｜UBS has lowered ServiceNow's target price from $170 to $100 and downgraded its rating from "Buy" to "Neutral". (GLONGHUI)

Glonghui, April 13 — Biotechnology company Replimune (REPL.US) fell more than 56% to $2.09 before market open. According to reports, Replimune’s core drug RP1 failed to obtain FDA approval. On April 10, 2026, the FDA issued a Complete Response Letter (CRL), officially rejecting the drug’s marketing application. The FDA rejected the RP1 application once again, citing insufficient clinical trial design and data inadequate to support its efficacy. Although the drug itself showed decent efficacy and safety data, the FDA has set stricter evidence standards for the “accelerated approval” pathway. This marks the second major setback for RP1 since its first rejection in July 2025.

Golden Ten Data, April 13 — Recently, market sources reported that lithium mine exports in Zimbabwe have shown signs of easing, and currently, several Chinese-funded enterprises have already obtained export qualifications; the specific quota is expected to be announced soon. In response, a staff member from Shengxin Lithium Energy confirmed today that the company’s local team has been in communication with Zimbabwean government departments. Although they did not explicitly mention having obtained the export license, they stated that “there has been substantial progress now” and “as soon as they grant the quota, exports may happen very soon. There were no specific implementation details before.” The staff member added that, although the specific quota figures are not yet known, “the export volume we require will be sufficient.”